Janik P, Roszkowski W, Ko H, Szmigielski S, Pulverer G, Jeljaszewicz J
J Cancer Res Clin Oncol. 1980; 98(1):51-8.
PMID: 7451553
DOI: 10.1007/BF00413176.
Krahenbuhl J, Humphres R, Henika P
Infect Immun. 1982; 37(1):183-8.
PMID: 7049949
PMC: 347509.
DOI: 10.1128/iai.37.1.183-188.1982.
Souter R, Gill P, GUNNING A, Morris P
Br J Cancer. 1981; 44(4):496-501.
PMID: 7028069
PMC: 2010816.
DOI: 10.1038/bjc.1981.217.
HOLLMANN K, VERLEY J
Experientia. 1980; 36(10):1213-5.
PMID: 6774883
DOI: 10.1007/BF01976136.
Kurashige S, Mitsuhashi S
Cancer Immunol Immunother. 1982; 14(1):1-3.
PMID: 6760962
PMC: 11039144.
DOI: 10.1007/BF00199423.
Immunostimulation. Clinical and experimental perspectives.
Drews J
Klin Wochenschr. 1984; 62(6):254-64.
PMID: 6716911
DOI: 10.1007/BF01721886.
Decreased monocyte antibody-dependent cell-mediated toxicity in stage I-II malignant melanoma. Augmentation by subcutaneous Corynebacterium parvum.
Murray J, Lee E
Cancer Immunol Immunother. 1984; 17(1):66-8.
PMID: 6563946
PMC: 11039194.
DOI: 10.1007/BF00205500.
The growth and spontaneous dissemination of melanoma B16 and Lewis lung tumour in two sub-strains of C57BL/6J mice treated with Corynebacterium parvum and/or levamisole.
BOERYD B, Benktson A
Clin Exp Metastasis. 1983; 1(3):289-95.
PMID: 6546203
DOI: 10.1007/BF00736411.
Comparison of antitumor activity of Lactobacillus casei with other bacterial immunopotentiators.
Yasutake N, Ohwaki M, Yokokura T, Mutai M
Med Microbiol Immunol. 1984; 173(3):113-25.
PMID: 6438456
DOI: 10.1007/BF02123760.
Paradoxical presence of T cell anergy during successful T cell-dependent tumour immunotherapy: characterization of a state of T cell 'amnaesia' following systemic administration of C. parvum.
McBride W, Howie S
Clin Exp Immunol. 1984; 57(1):139-48.
PMID: 6235074
PMC: 1536085.
Anti-tumour effect of humoral and cellular immunities mediated by a bacterial immunopotentiator, Lactobacillus casei, in mice.
Yasutake N, Ohwaki M, Mutai M, Koide Y, Yoshida T
Cancer Immunol Immunother. 1985; 20(2):109-16.
PMID: 3930065
PMC: 11038004.
DOI: 10.1007/BF00205676.
Synergistic anti-suppressor effect of mini cells prepared from Salmonella typhimurium and mitomycin C in EL 4-bearing mice.
Kurashige S, Akuzawa Y, Mitsuhashi S
Cancer Immunol Immunother. 1985; 19(2):127-9.
PMID: 3157437
PMC: 11039077.
DOI: 10.1007/BF00199720.
Distribution of intrapleural and intravenous Corynebacterium parvum in humans; 99mTc-, and 131I-labeled bacteria.
Kaufmann M, Marqverson J, Stanley K, MOURITZEN C
Cancer Immunol Immunother. 1986; 22(1):56-61.
PMID: 3011262
PMC: 11038980.
DOI: 10.1007/BF00205717.
Abrogation of the anti-metastatic activity of C. parvum by antilymphocyte serum.
Sadler T, Castro J
Br J Cancer. 1976; 34(3):291-5.
PMID: 1086096
PMC: 2025184.
DOI: 10.1038/bjc.1976.165.
Active specific immunotherapy of mouse methylcholanthrene induced tumours with Corynebacterium parvum and irradiated tumour cells.
Bomford R
Br J Cancer. 1975; 32(5):551-7.
PMID: 1082344
PMC: 2024810.
DOI: 10.1038/bjc.1975.260.
Effect of local injection of Corynebacterium parvum on the growth of a murine fibrosarcoma.
Woodruff M, Dunbar N
Br J Cancer. 1975; 32(1):34-41.
PMID: 1080671
PMC: 2024788.
DOI: 10.1038/bjc.1975.131.
Effects of Corynebacterium parvum treatment and Toxoplasma gondii infection on macrophage-mediated cytostasis of tumour target cells.
Krahenbuhl J, Lambert Jr L, Remington J
Immunology. 1976; 31(6):837-46.
PMID: 992714
PMC: 1445180.
Effect of C. parvum and active specific immunotherapy on intracerebral transplants of a murine fibrosarcoma.
Woodruff M, Hitchcock E, Whitehead V
Br J Cancer. 1977; 35(5):687-92.
PMID: 861152
PMC: 2025498.
DOI: 10.1038/bjc.1977.105.
Radiolabelling of Corynebacterium parvum and its distribution in mice.
Sadler T, Cramp W, Castro J
Br J Cancer. 1977; 35(3):357-68.
PMID: 851511
PMC: 2025284.
DOI: 10.1038/bjc.1977.50.
The effect of gold salts on tumour immunity and its stimulation by Corynebacterium Parvum.
McBride W, Tuach S, Marmion B
Br J Cancer. 1975; 32(5):558-67.
PMID: 813755
PMC: 2024804.
DOI: 10.1038/bjc.1975.261.
